Inventage Lab will be attending ChinaBio™ Partnering Forum 2026, taking place April 28–29, 2026 at Kerry Hotel Pudong, Shanghai, China.
ChinaBio™ Partnering Forum is Asia's premier BD partnering event for cross-border life science partnerships, bringing together 1,000+ industry leaders from over 30 countries and facilitating 4,000+ one-on-one partnering meetings. The forum serves as a key global dealmaking platform where leading pharma, biotech, and investment organizations converge to explore licensing, co-development, and strategic collaboration opportunities.
Inventage Lab is a publicly listed, clinical-stage biotech headquartered in South Korea, developing proprietary microfluidic-based drug delivery platforms. Our portfolio includes DrugFluidic®, a platform for small molecule long-acting injectable (LAI) formulations; BioFluidic™, designed to optimize subcutaneous delivery of antibodies and protein therapeutics; and GeneFluidic®, an LNP-based delivery platform for nucleic acid therapeutics. Each platform is engineered to overcome the limitations of conventional formulations and to maximize the pipeline value of our global partners.
At ChinaBio™ 2026, Inventage Lab will be available for one-on-one partnering meetings to explore co-development, licensing, and CDMO partnership opportunities across oncology, metabolic disease, neurology, and CNS indications. We welcome inquiries from pharma and biotech companies seeking differentiated formulation technologies to advance their global pipelines.
